IMS partnership with Yahoo

As new techniques enter the market, the "provability" of the digital model is becoming even more compelling. One such innovation comes from the IMS Health, which everyone seems to agree is the 800-pound gorilla in the Rx analytics business. 

Traditionally, IMS has been the place to go for analytics because they had the most Rx data. And lately, they have brought some innovation to the market through their partnership with Yahoo. 

IMS is now able to cross their 280 million patient records with Yahoo's 175 million consumer database, coming up with an overlapping group of 100 million patients. That level of granularity is unprecedented in the industry. Consequently, IMS can provide pharma marketers with more precise measurement of patient behavior even for relatively small brands. 
 

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023

Patent expiry hits profitability of top 15 global pharma companies in 2012

International pharmaceutical companies' are passing through difficult phase and are facing challenging operating environment with loss of patent exclusivity and limited R&D success. The pharmaceutical sales, including generics, eye care and vaccines, of 15 leading companies declined by 1.4 per cent to $433 billion during 2012 from $439 billion in the previous year. Novartis has overtaken Pfizer in pharmaceutical sales during 2012 and jumped to first rank from its second place in the previous year. Pfizer's pharmaceutical sales declined with loss of patent exclusivity for five products namely Lipitor, Xalatan, Aromasin, Geodan and Detrol during last couple of years in US, Europe and other markets.

GSK gives a Jump Start to "Electroceuticals"

In this week's Nature, GSK have announced their initiative to work with the global scientific community to develop bioelectronic medicines. These micro- and nanoscale devices, so-called "electroceuticals", will aim to control biological processes and treat disease by modulating the electrical impulses that travel along nerves, so to restore a healthy status quo of specific organs and functions. It is acknowledged that "to develop treatment devices, bioengineers designing biocompatible interfaces will need to collaborate with electrical engineers to develop microchips for real-time signal processing; with nanotechnologists to create energy sources; and with neurosurgeons to ensure that these designs can be implanted and connected." 

To catalyse  and show its commitment to this new field GSK is offering some incentives to integrate the scientific community around fundamental challenges. It has launched a exploratory funding program which will fully fund up to 40 researchers in up to 20 external labs, to conduct exploratory work mapping disease-associated neural circuits. It is open for applications throughout 2013. Funding will be rewarded on a rolling basis after a one-month review and approval process. 

Secondly, working with InnoCentive, GSK have launched a challenge competition to identify a specific disorder that can serve as a proof-of-principle test for electroceutical solutions. The challenge has a total purse of $5,000 and a deadline of 11 May 2013 for proposals.